A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections

Clinical Infectious Diseases

Volumn 61, Issue 11, 2015, Pages 1671-1678

  Knitsch, Wolfgang ^a   Vincent, Jean Louis ^d   Utzolino, Stefan ^b   François, Bruno ^e   Dinya, Tamás ^g   Dimopoulos, George ^h   Özgüneş, Ilhan ⁱ   Valía, Juan Carlos ^j   Eggimann, Philippe ^l   León, Cristóbal ^k   Montravers, Philippe ^f   Phillips, Stephen ^m   Tweddle, Lorraine ⁿ   Karas, Andreas ⁿ   Brown, Malcolm ^o   Cornely, Oliver A ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d ERASME HOSPITAL   (Belgium)

^e DUPUYTREN UNIVERSITY HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g UNIVERSITY OF DEBRECEN   (Hungary)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁱ ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m Chiltern International   (Netherlands)

ⁿ Astellas Pharma EMEA   (United Kingdom)

^o ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

more..

Author keywords

gastrointestinal surgery; intensive care; invasive candidiasis; micafungin; Preemptive antifungal therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; BIOLOGICAL MARKER; MICAFUNGIN; PLACEBO; BETA GLUCAN; BETA-1,3-D-GLUCAN; ECHINOCANDIN; LIPOPEPTIDE;

ABDOMINAL INFECTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GASTROINTESTINAL SURGERY; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; YOUNG ADULT; ADOLESCENT; BLOOD; CANDIDIASIS, INVASIVE; CLINICAL TRIAL; INTRAABDOMINAL INFECTIONS; POSTOPERATIVE COMPLICATIONS; PRE-EXPOSURE PROPHYLAXIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BETA-GLUCANS; BIOMARKERS; CANDIDIASIS, INVASIVE; DOUBLE-BLIND METHOD; ECHINOCANDINS; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTRAABDOMINAL INFECTIONS; LIPOPEPTIDES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRE-EXPOSURE PROPHYLAXIS; YOUNG ADULT;

EID: 84952065818     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ707     Document Type: Article

References (34)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
2. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004; 39(suppl 4): S185-92.
3. Schelenz S. Management of candidiasis in the intensive care unit. J Antimicrob Chemother 2008; 61(suppl 1):i31-4.
4. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
5. Garey KW, Rege M, PaiMP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
6. Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care 2010; 16:465-9.
7. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011; 1:37.
8. Cornely OA, Bassetti M, Calandra T, et al. ESCMIDguideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18(suppl 7):19-37.
9. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149:2349-53.
10. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3:685-702.
11. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220:751-8.
12. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43:235-43.
13. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-6.
14. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (Candida score) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-7.
15. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the Candida score for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37:1624-33.
16. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-72.
17. He YM, Lv XS, Ai ZL, et al. Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. World J Gastroenterol 2003; 9:2619-21.
18. Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122:147-51.
19. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36:20-5.
20. Ables AZ, Blumer NA, Valainis GT, Godernick MT, Kajdasz DK, Palesch YY. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospecive double-blind, randomized, placebo-contorolled trial. Infect Dis Clin Pract 2000; 9:169-75.
21. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebocontrolled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-8.
22. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-17.
23. Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149:83-90.
24. Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in highrisk adults in the critical care setting. Clin Infect Dis 2014; 58: 1219-26.
25. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3:772-85.
26. Bassetti M, Marchetti M, Chakrabarti A, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013; 39:2092-106.
27. Montravers P, Dupont H, Eggimann P. Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis. Intensive Care Med 2013; 39:2226-30.
28. Hanson KE, Pfeiffer CD, Lease ED, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012; 7:e42282.
29. Bailly S, Bouadma L, Azoulay E, et al. Failure of empirical systemic antifungal therapy in mechanically-ventilated critically ill patients. Am J Respir Crit Care Med 2015; 191:1139-46.
30. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97.
31. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883-93.
32. Mohr JF, Sims C, Paetznick V, et al. Prospective survey of (1→3)-β-Dglucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49:58-61.
33. Posteraro B, De Pascale G, Tumbarello M, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care 2011; 15:R249.
34. Tissot F, Lamoth F, Hauser PM, et al. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013; 188:1100-9.